NCT07502521 (SHIELD-MI) is a Phase 2 clinical trial of Dexrazoxane in Acute Myocardial Infarction (AMI), sponsored by Rohan Dharmakumar.

Who is sponsoring NCT07502521?

NCT07502521 is sponsored by Rohan Dharmakumar.

What drugs are being tested in NCT07502521?

Interventions in NCT07502521: Dexrazoxane, Normal Saline.

What condition does NCT07502521 study?

NCT07502521 studies Acute Myocardial Infarction (AMI).

Is NCT07502521 still recruiting?

NCT07502521 is currently completed. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT07502521: SHIELD-MI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexrazoxane to Protect Against Hemorrhagic STEMI

Completed Phase 2 Last updated 13 April 2026

What this trial tests

Phase 2 trial testing Dexrazoxane in Acute Myocardial Infarction (AMI) in 50 participants. Completed in 16 March 2026.

Timeline

30 August 2025

Primary endpoint
15 February 2026

16 March 2026

Quick facts

Lead sponsor	Rohan Dharmakumar
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	triple
Primary purpose	treatment
Enrollment	50
Start date	30 August 2025
Primary completion	15 February 2026
Estimated completion	16 March 2026
Sites	1 location across India

Drugs / interventions tested

Dexrazoxane (DEXRAZOXANE) — full drug profile →
Normal Saline

Conditions studied

Acute Myocardial Infarction (AMI) — all drugs for Acute Myocardial Infarction (AMI) →

Sponsor

Rohan Dharmakumar — full company profile →

Who can join

Adults 18 to 79, any sex, with Acute Myocardial Infarction (AMI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase Ila trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexrazoxane

Trials testing the same drug.

NCT06647953 — Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an An · Phase 3 · recruiting
NCT06220032 — Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma · Phase 3 · recruiting
NCT05858710 — Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma · Phase 1 · completed
NCT05292664 — Venetoclax Basket Trial for High Risk Hematologic Malignancies · Phase 1 · recruiting
NCT03930680 — Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane · Phase 1 · completed

Other recruiting trials for Acute Myocardial Infarction (AMI)

Currently open trials in the same condition.

NCT07400601 — A Clinical Cohort Registry Study on Primary PCI for Acute Myocardial Infarction at Zhongshan Hospital · recruiting
NCT07208006 — Very Early PCSK9 Inhibition for Acute Myocardial Infarction · NA · recruiting
NCT07537296 — Coronary and Myocardial Evaluation by Cardiac CT for Acute Myocardial Infarction · recruiting
NCT07276282 — Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction · Phase 3 · recruiting
NCT07293923 — Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock · NA · recruiting

Other Rohan Dharmakumar trials

Trials by the same sponsor.

NCT06162039 — National Landscape of Hemorrhagic Myocardial Infarction in the United States · completed
NCT06423625 — Hemorrhagic MI Prediction Score Model · completed
NCT06851325 — Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes · completed
NCT05604131 — Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients · Phase 2 · recruiting
NCT05872308 — Hemorrhagic Myocardial Infarction Detection by Post-reperfusion Troponin Kinetics · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07502521 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rohan Dharmakumar
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07502521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing